Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.
复制标题
DOI：
10.3802/jgo.2017.28.e45
复制
发表时间：
2017-05
影响因子：
3.9
通讯作者：
Kim JW
中科院分区：
文献类型：
--
作者：
Suh DH;Kim M;Kim K;Kim HJ;Lee KH;Kim JW
2016年入选妇科肿瘤学重大研究进展13个课题。对于卵巢癌，研究结果支持先前关于手术预防策略的报道。有几种靶向药物在III期试验中显示出类似的反应，包括尼拉帕尼、西地尼布和尼达尼布。与我们的预期相反，与传统的三周化疗方案相比，剂量密集的每周化疗方案未能证明更好的生存结果。对于复发性部分铂敏感卵巢癌患者，单药非铂治疗延长无铂间期并没有改善甚至恶化总生存期（OS）。对于宫颈癌，我们回顾了大规模人群研究的有力证据和扩大人乳头瘤病毒（HPV）疫苗覆盖率的无价疫苗的成本效益。本文对局部晚期宫颈癌（LACC）的治疗标准进行了综述。报告了从诊断到手术的适当手术等待时间的新发现。微创手术优于传统剖腹手术的优点再次得到证实。有5个新的基因区域会增加患子宫内膜癌的风险。放射治疗方面，发布了子宫内膜癌术后放疗（Post-Operative radiation therapy in endomecancer， PORTEC）-3生活质量（quality of life， QOL）数据，并报道了图像引导下适应性近距离放疗在LACC中有较高的局部控制率。此外，还有4个一般肿瘤学主题：生命末期化疗、重组t细胞免疫治疗、精准医疗的实现以及实现个性化癌症治疗的人工智能（AI）。对于乳腺癌，介绍了适应性随机试验，延长芳香酶抑制剂治疗，以及核糖素和帕博西尼。
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS). For cervical cancer, we reviewed robust evidences of larger-scaled population-based study and cost-effectiveness of nonavalent vaccine for expanding human papillomavirus (HPV) vaccine coverage. Standard of care treatment of locally advanced cervical cancer (LACC) was briefly reviewed. For uterine corpus cancer, new findings about appropriate surgical wait time from diagnosis to surgery were reported. Advantages of minimally invasive surgery over conventional laparotomy were reconfirmed. There were 5 new gene regions that increase the risk of developing endometrial cancer. Regarding radiation therapy, Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC)-3 quality of life (QOL) data were released and higher local control rate of image-guided adaptive brachytherapy was reported in LACC. In addition, 4 general oncology topics followed: chemotherapy at the end-of-life, immunotherapy with reengineering T-cells, actualization of precision medicine, and artificial intelligence (AI) to make personalized cancer therapy real. For breast cancer, adaptively randomized trials, extending aromatase inhibitor therapy, and ribociclib and palbociclib were introduced.